Clinical Geneticist and Board Certified Neurologist with extensive clinical and research experience on the faculty of the Johns Hopkins University School of Medicine and significant industry experience in Translational Medicine within four major pharmaceutical companies.  Technical expertise in early clinical development with small and large molecule therapeutics and development of biomarkers.  Known for leading academic-industrial collaborations, including as a founding member of the Alzheimer Disease Neuroimaging Initiative (ADNI) where he continues on the Publications Core and the Industrial Scientific Advisory Board. Led group at Wyeth to make the first joint Voluntary Genome Data Submission to the FDA and the EMEA. 

EDUCATION:

Senior Clinical Consultant, Biologics Consulting Group, Inc., Devon PA.

• Expertise in neurological disorders, mendelian disorders and translational medicine Charged with utilizing broad clinical and industrial expertise to assist clients in the following areas:
  • Short and long term translational and early clinical strategies for both neurological and mendelian disorders
  • Assisting clients with strategy and development of preclinical testing and other product development issues
  • Assisting clients in preparing for FDA meetings and FDA Advisory Panel meetings
  • Assisting in the preparation of RFDs, Pre-IDEs, IDEs, 510(k)s and PMAs

Assistant Vice President, Discovery, Translational Medicine, Pfizer, Collegeville PA,

• Development of Clinical and Translational plan for Multiple Sclerosis, Stroke and MS Learn Team
  Oversight of Neuroscience programs in Translational Medicine, including
  • Collaborations with TMRC investigators in schizophrenia, bipolar disease, ischemic stroke, P1Vital
  • Alzheimer Disease Neuroimaging Initiative (ADNI) Industrial Scientific Advisory Board & Publications Core

Assistant Vice President, Discovery Translational Medicine, Wyeth Research, Collegeville PA.

• Discovery Medicine was merged with the translational activities of Clinical Pharmacology, Experimental Medicine and Genomics into Translational Medicine
• Responsible for the development and validation of biomarkers. 
• Major accomplishment: adoption of a Wyeth policy requiring a biomarker strategy for all compounds entering Early Clinical development. 
• In addition to those made at the Scottish TMRC (described below), other specific accomplishments include:
  • Adoption of MIT robotic arm into critical path for stroke development
  • Modification of Alzheimer transgenic mouse model to exhibit the oxidative changes seen in the human disease
  • Clinical and preclinical studies of amyloid dynamics in cerebrospinal fluid, development of sensitive myostatin assay, resulting in pharmacokinetic analyses of gamma secretase treatment on beta amyloid levels in mouse models of Alzheimer disease and incorporation into Alzheimer Disease strategy by Learn Council
  • Brought Wyeth into ADNI (Alzheimer Disease Neuroimaging Initiative) for which I am industrial representative on the Publications Core.

Director, Translational Medicine Research Collaboration, Wyeth Research; Dundee, Scotland, Assistant Vice President, Translational Research, Professor (Hon.) of Medicine, Dentistry and Nursing, University of Dundee.

• Co-founder of the Translational Medicine Research Collaboration between the four medical schools in Scotland (Universities of Aberdeen, Dundee, and Edinburgh), the Scottish National Health Service, Scottish Enterprise, and Wyeth Translational Medicine. 
  • This consortium is organized on a hub and spoke model. 
  • Hub laboratory at the University of Dundee we currently employs 32 scientists and physicians, of whom 12 are Wyeth employees, the remainder employees of the University of Dundee. 
  • In the 68 research collaborations with the spoke institutions there have been over 200 investigators.
  • Personal and group accomplishments under my leadership included:
    • First rodent model of schizophrenia based on pathogenic human mutation: development and delivery to Wyeth Neuroscience Discovery of transgenic mouse model of schizophrenia based on a chromosomal translocation in Scottish high-density kindred, the first rodent model of a highly prevalent psychiatric based on an authentic pathogenic human mutation, published in Journal of Neuroscience
    • Development of mass spectrophotometric assay of phosphorylated kinases with 5 log dynamic range, adaptable to all soluble phosphorylated proteins.
    • Genome wide association and confirmatory study of large Scottish cohort of  schizophrenia and bipolar disease
    • Development of a novel sensitive and quantitative assay for measurement of matrix metalloproteinase 12 in sputum of patients with COPD
    • Identification of a genetic haplotype associated with a 40-fold enrichment of early onset osteoporosis
    • Genetic subgrouping, mutation quantification and transcriptional signatures of human colon cancer
    • First Wyeth programs for development of novel PET and SPECT ligands from Wyeth equity
    • Winner of 2007 European Foundation award for Best Inward Investment
    • Honorary Professorship University of Dundee School of Medicine, Dentistry and Nursing
    • Faculty, ESMEC, European Society for Medicinal Chemistry, Urbino, Italy
    • Reviewer for the Medical Research Council industrial-academic programmes

Assistant Vice-President, Discovery Medicine, Wyeth Research, Collegeville PA and Cambridge MA

• Assembled and managed a group of 28 physicians and scientists responsible for the alignment of Discovery Research activity with human disease.
  • This group provided support for all five therapeutic areas in Wyeth Research:  Oncology, Cardiovascular and Metabolic, Inflammatory, Neuroscience, Women’s Health and Bone. 
  • Member of Discovery Executive Council, Discovery Review Board, Exploratory Medicine Advisory Board, and Development Council. 
  • Our remit was the evaluation of existing biomarkers for animal and human studies, as well as the identification and validation of novel markers with biochemical, physiological, imaging, and microarray techniques, as well as provision of genomic support for Experimental Medicine and the Clinical Development.  Accomplishments included:
    • Identification of pretreatment genomic signatures in peripheral blood monocytes predictive of meningoencephalitis in Alzheimer patients actively immunized with beta amyloid. Results published in Archives of Neurology.
    • Development of sensitive immunoassay for detection of active myostatin in human serum
    • Entry of Wyeth into Alzheimer Disease Neuroimaging Initiative (ADNI)
    • First voluntary submission of clinical transcriptional profiling data to FDA and EMEA.
    • Organizing Committee for the annual Branch Creek Conference, an annual symposium for senior FDA and industrial leaders

Director, Exploratory Medical Sciences, Neurology-GI Centre for Excellence in Drug Discovery (CEDD), Harlow, UK

• Became SB employee, taking leave of absence from Johns Hopkins.
• Assembled and managed a team of six neurologists and gastroenterologists in Investigational Medicine. 
• After the merger with Glaxo my responsibilities in the Neurology CEDD included:
  • Oversight of Neurology & GI Translational Medicine at GSK/Addenbrooke's (25 projects; $7.5 M)
  • Preclinical studies with PPAR gamma agonists, and advocacy for clinical studies in Alzheimer Disease, subsequently pursued by GSK
  • Membership in nine person working group: responsible for study design, subject characterization, neuropsychological measures & statistical issues for the NIA AD Neuroimaging Initiative, now ADNI.
  • Executive Committee of the Neurology/GI CEDD; PRG (portfolio review group), TAST (therapeutic area strategy team), Cross-CEDD PPAR Coordination Team, Surrogate Matrix Team
  • Sponsorship of a study of serial volumetric MRI measures that distinguished rate of brain atrophy in Alzheimer disease from controls, as efficacy biomarker (MIRIAD). Methods developed in this project are now in use by ADNI.
  • Identification of gap junctions as the site of action of carabersat and tonabersat. for legacy SB antiepileptic and antimigraine compounds. This led to the retrieval of outlicensed assets and reinstitution of development program
  • Championing a new paradigm for testing neuroprotection in stroke: preoperative identification of a subgroup of Coronary Artery Bypass Graft (CABG) patients with >20% risk of new stroke perioperatively
  • Joint Development Committee of Shionogi-GSK Joint Venture, with oversight of  $45M development programme for one AIDs and four neurology compounds
  • Institution of collaborations for mechanism-based pain treatment trials
  • Neuroscience Therapeutic In-Licensing -- reviewed 18 opportunities, of which 3 progressed
  • Elan Beta Bloc Due Diligence Team
  • Phase 3 SmithKline Beecham- GlaxoWellcome Integration Team on developability criteria
  • Review of cross-TAT activities, with specific proposals for IL8, carvedilol, Avandia
  • Central MAP team for SB342219; co-author of development plan; 342219 Clinical Working Group
  • Discovery representative to Key Opinion Leader committee
  • Assistance of Sir Colin Dollery in his reviews of Institutional collaborations with Harvard Partners and with Stanford University

Senior Consultant in Neurogenetics, SmithKline Beecham Pharmaceuticals, Harlow, UK

• Sabbatical year from Johns Hopkins University School of Medicine to initiate genetics programmes in support of Neuroscience Discovery at SmithKline Beecham Pharmaceuticals.  Accomplishments included:
  • Aberdeen-Institute of Psychiatry collaboration for linkage and association studies in schizophrenia.  Results published in Nature Genetics.
  • Comparison of linkage disequilibrium of SNPs and micro satellites in West Grampian
  • Establishment and management of IOP-King's collaboration in genetics of narcolepsy
  • Securing Millennium-NIMH schizophrenia sample sets
  • Planning and monitoring teams for genetics of neurological and psychiatric diseases
  • Strategy documents in schizophrenia, depression, pain

Fellow in Neurology with advancement to Associate Professor. The Johns Hopkins University School of Medicine.

• Clinical duties in general neurology, neurogenetics, adult and pediatric genetics.
• Teaching of residents, medical students, graduate students in genetics and in neuroscience.
• Laboratory-based research in genetics and cell biology of heritable neurological disorders with a focus on mitochondrial diseases.
• Accomplishments included:
  • Over 200 publications in peer-reviewed literature including first molecular definition of a pathogenic mitochondrial DNA deletion, identification of the molecular basis of the myoneurogastrointestinal syndrome, FACs isolation of human muscle progenitors, segregation model of Tourette syndrome
  • Author-Editor for Neurologic, Psychiatric and Muscular Disorders, Online Mendelian Inheritance in Man  and co-author with V.A. McKusick & colleagues of the last print edition of Mendelian Inheritance in Man, JHU Press
  • Co-author, The Primary Care Physician's Guide to Common Psychiatric and Neurologic Problems, JHU Press
  • Director, Neurology and Neurosurgery Consultation Center of the Johns Hopkins Hospital
  • Clinical Director, Greenberg Centre for Skeletal Dysplasia in the Division of Medical Genetics, Director, Neurogenetics Service.  Joint appointments in Pediatrics, Medicine, and Neurological Surgery.
  • Director of Neurology Residency Selection Committee
  • Scientific Advisory Board, Kennedy-Krieger Institute
  • Consultant to Genentech, Merck, SmithKline Beecham
  • Reviewer: Genomics, American Journal of Human Genetics, Neurology, Human Molecular Genetics, New England Journal of Medicine, Medicine. Molecular & Cellular Neuroscience
  • Editor:  Molecular Neurobiology, Neuroscience Forum, The Scientific World, Mitochondrion
  • American Neurological Association, American Academy of Neurology, American Society for Human Genetics

1978-1980

Fellow and Resident, Neurology, The John Hopkins Hospital, Baltimore, Maryland

Medical Intern, St. Luke’s Hospital Medical Center, New York, New York

ACCREDITATION:

• Diplomate of American Board of Medical Examiners; Maryland License D18639
• Board Certified in Neurology (#26607) UP1N # 69902
• General Medical Council (UK) Temporary Registration (renewable)

BOARDS:

• Industrial Scientific Advisory Board, Alzheimer Disease Neuroimaging Initiative (ADNI), 2001- present
• Scientific Advisory Board, World Drug Manufacturing Summit, 2009
• Scientific Advisory Board, World Trade Group Life Sciences, 2008-present
• Scientific Advisory Board, Translational Medicine Research Collaboration, 2004 to present
• Medical Advisory Board, Little People of America,  1994 – 2002
• Medical Advisory Board, Charcot-Marie Tooth International
• Medical Advisory Board, National Ataxia Foundation
• Medical Advisory Board, von Hippel Lindau Family Alliance
• Editorial Board, The Scientific World
• CHI Insight Pharma Reports Advisory Board
• Scientific Review Board, Institute for the Study of Aging

AWARDS:

• Presidential Scholar, appointed by Lyndon Baines Johnson
• National Merit Scholar
• Joseph P. Kennedy Foundation Scholar
• William O. Mosely, Jr., Travelling Fellow of Harvard University
• Honorary Life Member, Little People of America;
• Outstanding Alumnus Award, St. Xavier School;
• Honorable Mention for the Moore Award, American Association of Neuropathologists
• Johns Hopkins University Resident's Teaching Award
• Europe Foundation: Best Inward Investment Award, La Baule, France

PUBLICATIONS:

1. Hurko O and Jones GK (2011) Valuation of Biomarkers. Nature Reviews Drug Discovery 10: 253-254.
2. Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC; Alzheimer's Disease Neuroimaging Initiative, Goate AM. (2011) Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS One. 6:e15918.
3. Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C; Alzheimer's Disease Neuroimaging Initiative (2010) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative.  Arch Neurol. 67: 1370-8.
4. Hurko O. Boudonck K, Gonzales C, Hughes ZA, Jacobsen JS, Reinhart PH, Crowther D. (2010) Ablation of the locus coeruleus increases oxidative stress in tg-2576 transgenic but not wild-type mice. International Journal of Alzheimers Disease. 864625
5. Hurko, O (2010) Future Drug Discovery and Development.  Molecular Genetics & Metabolism, 100: S92- 96.
6. Chavez J, Barone F, Feuerstein GF, Hurko O (2009) Pharmacologic interventions for stroke: Looking beyond the three hour window into the penumbra with biomarkers not a stopwatch.  Stroke, 40: 558-63.
7. Hurko, O (2009) The Uses of Biomarkers in Drug Development.  Annals of the New York Academy of Sciences1180:  1-10.
8. Hong I. Wan, Orest Hurko, Mark Day, J. Lynn Rutkowski (2009) Translational Medicine Perspective in Development of Disease Modifying Therapies Biomarkers for Alzheimer’s Disease: Biomarkers to Buy Down the Risk. Drug Development Research, 69 : 1–10
9. Chavez, J,  Zaleska, M, Wang, Xinkang; Wood, Andrew; Hurko, Orest; Pangalos, Menelas; Feuerstein, Giora, (2009) Multimodal Magnetic Resonance Imaging for assessing evolution of Ischemic Penumbra: A key Translational Medicine Strategy to manage the risk of developing novel therapies for acute ischemic stroke., Journal of Cerebral Blood Flow and Metabolism 29: 217-219.
10. Sanbing Shen, Bing Lang, Chizu Nakamoto, Feng Zhang, Serena Deiana, Soh-Leh Kuan, Jin Pu1, Jacques Micheau, Christina Chatz, Shui-Sheng He, Iain Mackie, Nicholas J. Brandon, Karen Marquis, Mark Day, Orest Hurko, Colin D. McCaig, Gernot Riedel, David St Clair (2008) Schizophrenia-related neural and behavioral  phenotypes in transgenic mice expressing truncated Disc1 .  J. of Neuroscience, 43:10893-10904.
11. Feuerstein G, Gill D, Dormer C, Ruffolo RR, J Lynn Rutkowski L, Walsh FS, Hurko O (2008) The Vastly Neglected Biomarkers Contributing to Early Clinical Development Failure: Molecular Imaging.  American Pharmaceutical Review May/June
12. Feuerstein, G., D. Gill, C. Dormer, R. Ruffolo, J. Rutkowski, F. Walsh, O. Hurko. (2008). Translational Medicine Perspectives in Drug Discovery and Development Part II: Target Compound Interaction-the Vastly Neglected Biomarkers Contributing to early Clinical Development Failure. American. Drug Discovery 3:48-54..
13. Feuerstein G,, Coughlin C, , Robert R Ruffolo Jr RR, Dormer C, Walsh FS, Hurko O,  J Rutkowski L (2007) Translational Medicine Perspectives in Drug Discovery and Development Part III: Disease Biomarkers - Setting the Lexicon Straight for Drug Registration, Drug Labelling: Prospects and Commercial Opportunities American Drug Discovery 3: 36 -42.
14. Wan HI. Day M., Hurko O,  Rutkowski JL (2007) Biomarkers for Alzheimer’s Disease: Translational Medicine Approaches in Development of Disease Modifying Therapeutics: Part 1. Biochemical Biomarkers for Disease-Modifying Therapeutics in Alzheimer’s Disease American Drug Discovery2:  44 -50.
15. Pangalos MN, Schechter LE, Hurko O (2007) Drug development for CNS disorders: strategies for balancing risk and reducing attrition.. Nature Reviews Drug Discovery 6: 521-532.
16. Hurko O (2006) The impact of preclinical drug safety on R&D productivity. Expert Opinion on Drug Discover, 1: 369-372
17. Hurko O, Ryan JL (2005) Translational research in central nervous system drug discovery.  NeuroRx. 2: 671-82
18. Hurko, O, Rutkowski, JL. (2005) Translational Medicine Breaks Bottlenecks. Drug Discovery & Development, 8 : 30-38.
19. Hurko O. (2001).  Genomic studies on neuropsychopharmacology: Implications for drug discovery. European Neuropsychopharmacology. 11::491-9.
20. McGinnis RE, Fox H, Yates P, Cameron L-A,. Barnes MR,. Gray IC, Spurr NK, Hurko  O & St. Clair D. (2001) Failure to confirm NOTCH4 association with schizophrenia in a large population-based sample from Scotland, Nature Genetics, 28: 128-129
21. Wright MJ, Ain MC, Clough MV, Bellus GA, Hurko O, McIntosh I (2000) Achondroplasia and nail-patella syndrome: the compound phenotype. Journal of Medical Genetics 37:E25
22. Hurko O, Walsh FS. . (2000) Novel drug development for Amyotrophic Lateral Sclerosis. Journal of Neurological  Sciences,  180 :21-28.
23. Elmaci I, Ain; Michael J. Wright; Roland R. Lee; Jeannie-Marie E. Sheppard; Daniele Rigamonti; Orest Hurko (2000) Perioperative Intracranial Hemorrhage in Achondroplasia: Journal of  Neurosurgical Anesthesia 12: 217 -221
24. Crockett MM, Carten M, Hurko O, Sponseller P.(2000) Motor milestones in diastrophic dysplasia. Journal of Pediatric Orthopedics 20: 437-41.
25. Ain MC, Elmaci I, Hurko O, Clatterbuck RE, Lee RR, Rigamonti D .(2000) Reoperation for spinal restenosis in achondroplasia.  Journal of Spinal Disorders 13:168-73
26. Crawford TO, Sladky JT, Hurko O, Besner-Johnston A, Kelley RI (1999).Abnormal fatty acid metabolism in childhood spinal muscular atrophy Annals of  Neurology;45: 337-43
27. Hurko O, Provost TT. (1999)  Neurology and the skin. Journal of Neurology, Neurosurgery and Psychiatry  ;66:417-30
28. Becher MW, Wills ML, Noll WW, Hurko O, Price DL  (1999);Kearns-Sayre syndrome with features of Pearson's marrow-pancreas syndrome and a novel 2905-base pair mitochondrial DNA deletion. Human Pathology 30: 577-81
29. Bellus GA, Bamshad MJ, Przylepa KA, Dorst J, Lee RR, Hurko O, Jabs EW, Curry CJ, Wilcox WR, Lachman RS, Rimoin DL, Francomano CA. (1999) Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. American Journal of  Medical Genetics85: 53-65 
30. Mogayzel PJ, Carroll J, Loughlin GM, Francomano C, Hurko O, Marcus C (1998)  Sleep-disordered breathing in children with achondroplasia.  Pediatrics132:667-671.
31. Hurko O (1997) The explosion of neurogenetics.  Current Opinion in Neurology 10:  77-84.
32. Polymeropoulos MH, Hurko O, Hsu F, Rubinstein J, Basnet S, Lane K, Dietz II, Spetzler RF, Rigamonti D (1997) Linkage of the locus for cerebral cavernous hemangiomas to human chromosome 7q in four families of Mexican American descent Neurology 48: 752-757. 
33. Hurko O (1997) Recent advances in heritable ataxias.  Annals of Neurology,. 41: 4-6.
34. Versino M, Hurko O, Zee DS (1996) Disorders of binocular control of eye movements in patients with cerebellar dysfunction.  Brain119: 1933-1950.
35. Hofhaus G, Johns DR, Hurko O, Attardi G, Chomyn A. (1996) Respiration and growth defects in transmitochondrial cell lines carrying the 11778 mutation associated with Leber’s hereditary optic neuropathy Journal of Biological Chemistry271:13155-13161.
36. Hurko O (1996) Mitochondrial DNA and leukoencephalopathies. Molecular and Chemical Neuropathology 27: 88-93.
37. Walkup JT, Labuda MC, Brown J, Riddle MA, Singer HS, Hurko O (1996) Family study and segregation analysis of Tourette’s syndrome: Evidence for a mixed model of inheritance.  American Journal of Human Genetics, 59: 684-693.
38. Zeidman SM, Monsein LH, Arosarena O, Aletich V, Biafore JM, Dawson RC, DeBrun G, Hurko O (1995)  Reversibility of white matter changes and dementia after treatment of dural fistulas.  American Journal of Neuroradiology 16: 1080-1083.
39. DiDonato CJ, Morgan K, Carpten JD, Fuerst P, Ingraham SE, Prescott G, McPherson JD, Wirth B, Zerres K, Hurko O, Wasmuth JJ, Mendell JR, Burghes AHM, Simard LR (1994)  Association between AgI-CA alleles and severity of autosomal recessive spinal muscular atrophy.  American Journal of Human Genetics 55: 1218-1229.
40. Hurko O (1994) Mitochondrial DNA mutations in Leber’s Optic Neuropathy.  Annals of Neurology 35: 636.
41. Spencer F, Hugerat Y, Simchen G, Hurko O, Connelly C, Hieter P (1994)  Yeast kar1 mutants provide an efficient method for YAC transfer to new hosts.  Genomics, 22:  118-126.
42. Burghes AHM, Ingraham SE, Kote-Jarai S, Nakarni N, Rosenfeld S, Herta N, Hurko O, Florence J. Moxley RT, Cobben J, Mendell JR. (1994)  Linkage mapping of the spinal muscular atrophy gene.  American Journal of Human Genetics93: 305-312.
43. Uematsu S, Wang H, Kopits, S, Hurko O. (1994) Total craniospinal decompression in achondroplastic stenosis.  Neurosurgery 35: 250258.
44. Uematsu S, Hurko O. (1993) Neurosurgical considerations in skeletal dysplasia.   Neurosurgical Quarterly 3: 192-217
45. Lebo, RV, Chance PF, Dyck PJ, Redilaflores MT, Lynch ED, Golbus MS, Bird TD, King MC, Anderson LA, Hall J, Wiegant J, Jiang ZR, Dazin PF, Punnett HH, Schonberg SA, Moore K, Shull MM, Gendler S, Hurko O, Lovelace RE, Latov N, Trofatter J, Conneally PM (1993) Chromosome 1 Charcot-Marie-Tooth disease (CMT1B) locus in the Fc-gamma receptor gene region. Human Genetics 91: 301.
46. Lebo, RV, Martelli L, Su Y, Li L, Lynch E, Mansfield E, Pua K-H, Watson DF, Chueh J, Hurko O (1993)  Prenatal diagnosis of Charcot-Marie-Tooth disease type I by multicolor in situ hybridization, American Journal of Human Genetics 47: 441-450.
47. Yoneda M, Chomyn A, Martinuzzi A, Hurko O, Attardi G. (1992) Marked replicative advantage of human mtDNA carrying a point mutation that causes the MELAS encephalomyopathy. Proc. Natl. Acad. Sci. (USA) 89: 11164-11168.
48. Shuper A., DeRossett S., Hurko O. (1992) Confusion as the presenting manifestation of vertebral osteomyelitis.  Israeli Journal of Medical Sciences 28: 864-868.
49. Threlkeld, A., Miller NR., Golnick K., Griffin JW, Hurko O. (1992)  Ophthalmologic involvement in the myo-neuro-gastrointestinal encephalomyopathy (MNGIE) syndrome.  American Journal of Ophthalmology, 114: 322-328.
50. Kumar AJ, Naidich TP, Stetten G, Reiss AL, Wang AL, Thomas GH, Hurko O (1992)  Chromosomal disorders: background and neuroradiology.  American Journal of Neuroradiology.13: 577-593.
51. Chomyn A, Martinuzzi A, Yoneda M, Daga A, Hurko O, Johns D, Lai ST, Nonaka I, Angelini C, Attardi G (1992)  The MELAS associated mutation in the mtDNA binding site for the transcription termination factor causes protein synthesis and respiration defects, but does not affect the levels of upstream and downstream mature transcripts.  Proc. Natl. Acad. Sci (U.S.A) 89: 4221-4225.
52. Hurko O (1992) Primer on genetic techniques. Neuroscience Forum 2: 5-15.
53. Johns DR, Threlkeld AB, Miller NR, Hurko O (1992)  Multiple mitochondrial DNA deletions in myo-neuro-gastrointestinal encephalopathy syndrome.  American Journal of Ophthalmology.  115:  108-109.
54. Lunardi J, Hurko O, Engel WK, Attardi G (1992)  The multiple ADP/ATP translocase genes are differentially expressed during human muscle development.  Journal of Biological Chemistry. 267: 15267-15270.
55.  Johns D.R., Hurko O. (1991) Mitochondrial leucine tRNA mutation in neurological diseases. Lancet337: 927-928.
56. Lebo R.V., Chance P.F., Dyck P.J., Redila-Flores M.T., Lynch E.D., Golbus M.S., Bird T.D., King M.C., Anderson L.A., Hall J., Wiegart J., Jiang Z., Dazin P.F., Punnett H.H., Schonberg S.A., Moore K, Shull M.M., Gendler S., Hurko O., Lovelace R.E., Latov N., Troffater J., Conneally P.M. (1991) Chromosome 1 Charcot-Marie-Tooth disease (CMT 1B) locus in Fc-gamma receptor gene region.  Human Genetics 88: 1-12.
57. Hurko O. (1991) Human neurogenetics.  Neuroscience Facts 2: 1-2.
58. Aryanpur J., Hurko O., Francomano C., Wang H., Carson B. (1990)  Craniocervical decompression for cervicomedullary compression in pediatric patients with achondroplasia.  Journal of Neurosurgery. 73: 375-382.
59. Eleff S.M., Barker P.B., Blackband S.J., Chatham, J.C., Lutz N.W., Johns, D.R., Bryan, R.N., Hurko O. (1990) Phosphorus magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels of brain phosphocreatine.  Annals of Neurology 27: 626-630.
60. Hurko, O., Johns, D.R., Rutledge, S.L., Stine, O.C., Peterson, P.L., Martens, M.E., Drachman, D.B., Brown, R.H., Lee, C.P. (1990).  Heteroplasmy in chronic progressive external ophthalmoplegia:  Clinical and molecular observations. Pediatric Research 28: 542-548.
61. Rosen, S.A., Wang, H., Uematsu, S., Cornblath, D.R., Hurko, O. (1989) Compression syndromes due to hypertrophied nerve roots in hereditary motor sensory neuropathy type I.  Neurology 39: 1173-1177.
62. Johns, D.R., Rutledge, S.L., Stine, O.C., Hurko, O. (1989). Directly repeated sequences associated with pathogenic mitochondrial DNA deletions. Proc. Natl. Acad. Sci. (U.S.A) 86: 8059-8062.
63. Hurko, O., Johns, D.R. (1989).  Mosaic expression of dystrophin in Duchenne carriers.  New England Journal of  Medicine, 321: 398.
64. Johns, D.R., Hurko, O. (1989).  Preferential amplification and molecular analysis of human mitochondrial DNA with a pathogenetic deletion.  Genomics. 5: 623-628.
65. Johns, D.R., Drachman, D.B., Hurko, O. (1989). Identical mitochondrial DNA deletion in blood and muscle Lancet 1: 393-394.
66. Hurko, O., Hoffman, E., McKee, L.M., Johns, D.R., Kunkel, L. (1989). Dystrophin analysis in clonal myoblasts derived from a Duchenne muscular dystrophy carrier.  American Journal of Human Genetics 44: 820-826.
67. Hurko, O., Pyeritz R, Uematsu S. Neurological considerations in achondroplasia. (1988) Basic Life Sci. 48: 153-162.
68. Reid, C.S., Pyeritz, R.E., Kopits, S.E., Maria, B.L., Wang, G., McPherson, R.W., Hurko, O., Phillips, J.A. (1988). Cervicomedullary cord compression in achondroplasia; value of comprehensive neurologic and respiratory evaluation. Basic Life Sci. 48:199-206.
69. Streeten, E., Uematsu, S., Hurko, O., Kopits, S.E., Murphy, E., Pyeritz, R.E. (1988). Extended laminectomy for spinal stenosis in achondroplasia. Basic Life Sci ; 48:261-73
70. Uematsu, S., Wang, H., Hurko, O., Kopits, S.E. (1988).  The subarachnoid fluid space in achondroplastic spinal stenosis: the surgical implications. Basic Life Sci.  48:275-81.
71. Gahl, W.A., Bernardini, I., Dalakas, M., Rizzo, W.B., Hoeg, J.M., Hurko, O., Bernar, J. (1988).  Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. Journal of Clinical Investigation 81: 549-560.
72. Peden K, Hurko O, Tennekoon G (1987) Establishment of cell lines from primary cultures by transfection with SV40 large T antigen gene. Progress in Clinical Biological Research 253:101-9
73. Harper, G.S., Bernardini, I., Hurko, O., Zuurveld, J., Gahl, W.A. (1987). Cystine storage in cystinotic myotubes from patients with nephropathic cystinosis.  Biochemistry Journal 243: 841-845.
74. Hurko, O., McKee, L., Zuurveld, J.,  Swick, H. (1987).  Comparison of Duchenne and normal myoblasts from a single heterozygote. Neurology 37: 675-681.
75. Reid, C.S., Pyeritz, R.E., Kopits, S.E., Maria, B.L., Wang H., McPherson, R.W., Hurko, O., Phillips, J.A. (1987).  Cervicomedullary compression in young achondroplasts: Value of comprehensive neurologic and respiratory evaluation.  Journal of Pediatrics 110: 522-530.
76. Hurko, O., Reynafarje, B., Kuncl, R., Feldman, E., Stern, B. (1986).  Familial mitochondrial encephalomyopathy, lactic acidosis and stroke (MELAS) associated with cytochrome oxidase deficiency.  American J. Medical Genetics  25: 716-717.
77. Hurko, O., McKee, L., Zuurveld, J. (1986). Transfection of human skeletal muscle with the SV40 large T antigen gene linked to a metallothionein promoter.  Annals of Neurology 20: 573-582.
78. Moore, S.E., Hurko, O., Walsh, F.S. (1986).  Novel antigens at the neuromuscular junction.  Journal of Neuroimmunology 10: 185-200.
79. Moore, S.E., Hurko, O., Walsh, F.S. (1984).  Immunocytochemical analysis of fibre type differentiation in developing skeletal muscle.  Journal of Neuroimmunology7: 137-149.
80. Walsh, F.S., Moore, S.E., Woodroofe, M.N., Hurko, O., Nayak, R., Brown, S.M., and Dickson, J.G. (1984).  Characterization of human muscle differentiation antigens. Experimental Biology and Medicine 9: 50-56.
81. Hurko, O., Quinn, C.A., Brown, S.M., Gordon, R.D., Woodroofe, M.N., Walsh, F.S. (1984).  Immunogenetic characterization of human muscle cell surface.  Experimental Biology and Medicine 2: 41-49.
82. Walsh, F.S., Moore, S.E., Woodroofe, M.N., Hurko, O., Nayak, R., Brown, S.M., and Dickson, J.G. (1984).  Characterization of human muscle differentiation antigens. Experimental Biology and Medicine 9: 50-56.
83. Walsh, F.S., Hurko, O. (1983).  How to find a needle in a haystack – the product of the Duchenne muscular dystrophy gene.  Muscular Dystrophy Group Journal (Great Britain) pp. 1-12.
84. Hurko, O, Walsh, F.S. (1983).  Human fetal muscle specific antigen is restricted to regenerating muscle fibers in diseased adult human muscle.  Neurology 33: 737-743.
85. Aarabi, B., Pasternak, G., Hurko, O., Long, D.M. (1979).  Familial intradural spinal arachnoid cyst.  Journal of Neurosurgery, 50: 826-829.
86. Nirenberg, Marshall W., William L. Kline, Orest Hurko (1979) "Muscarinic Acetylcholine Receptors of Cultured Cell Lines". National Library of Medicine: NHLBI ReportsSeptember 1979.
87. Hurko, O. (1978).  Specific [3H]quinuclidinyl benzilate binding activity in digitonin solubilized preparations from bovine brain.  Archives of Biochemistry and Biophysics. 190: 434-445.
88. Nirenberg, Marshall W., William L. Klein, Orest Hurko, Wolfgang Burgermeister, Bernhard Witkop, "Muscarinic Acetylcholine Receptors of Cultured Cell Lines". National Library of Medicine: NHLBI Reports,September 1976.
89. Hurko, O., Elster, P., Wurtman, R.J. (1974).  Adenylate cyclase activity in the bovine adrenal medulla.  Endocrinology, 94: 591-594.
90. Lytle, L.D., Hurko, O., Romero, J.A., Cottman., Leehey, D., Wurtman, R.J. (1972).  The effects of 6-hydroxydopamine pretreatment on the accumulation of dopa and dopamine in the brain and peripheral organs following L-dopa administration.  Journal of Neural Transmission, 33: 63-71.

ABSTRACTS & PRESENTATIONS

91. Orest Hurko and Andrew Chadwick (2011) Estimating the value of biomarker for a drug development program for a neurological indication, American Society for Experimental Neurotherapeutics, Bethesda, Maryland.
92. Orest Hurko (2010)Valuation of nonsurrogate biomarkers. 9th Annual Drug Discovery & Development Summit. Copenhagen, Denmark
93. Orest Hurko (2010) Valuation of nonsurrogate biomarkers. 11th Annual Drug Discovery Leaders Summit, Montreux, Switzerland
94. Orest Hurko (2010) Identifying Opportunities for University-Industry R&D Collaborations. Project Portfolio Management in Pharma, Boston, Massachusetts
95. Orest Hurko (2010) Preclinical preparations for Early Phase Clinical Studies, 4th Annual Exploratory Clinical Development Europe 2010, London, UK
96. Orest Hurko (2010) Regulatory considerations for computerized test batteries, CANTAB Meeting, Utrecht, The Netherlands
97. Orest Hurko (2010) Valuation of biomarker programmes for early clinical development,  11th Annual Phase I Clinical Trials,London, UK
98. Orest Hurko (2010) Enriched patient groups: Biomarkers for selection of subjects, Exploratory Clinical Development World, Cambridge, Massachusetts
99.  Orest Hurko (2010) When are biomarker consortia appropriate?  Global Development Summit International, The Boulders, Arizona
100. Orest Hurko (2010) Valuation of neuroimaging biomarkers, MIPTEC ,Basel, Switzerland
101. Hurko O (2009) Future Drug Discovery for Rare Inherited Diseases of Intermediary Metabolism. Satellite Symposium to the 11th ICIEM, “Overcoming Barriers—New Developments and Future Directions for Urea Cycle Disorders, La Jolla, California.
102. Hurko O (2009) Biomarkers in psychiatry.  European College of Neuropsychopharmacology, Nice, France.
103. Hurko O (2009) Genomic /Genetic Considerations in CNS Drug Development: Current Status and Approaches -1. Basic Science Standpoint. ASENT: American Society of Experimental Therapeutics, 11th Annual Meeting, Arlington, Virginia
104. Hurko O (2009) The Use of Biomarkers in Drug Development.  NYAS Biomarkers in Brain Disease, Said Business School, Oxford University., Oxford, UK
105. Hurko O, Cathleen Gonzalez, Steve Jacobsen, Kurt Boudonck, Peter Reinhart. (2008) Lesioning the locus coeruleus in Tg2576 amyloid transgenic mice induces pxidative stress similar to that seen in human Alzheimer Disease.  Annals of Neurology 62: S42.
106. Hurko, O (2008) Biomarkers in psychiatry: a view from industry, British Association of Psychopharmacology, Harrogate, England
107. Hurko O (2008) Toward an integrated Biomarker delivery , 2nd Translational Medicine Investigators Research Meeting, Glasgow, Scotland
108. Hurko O (2008) Life Sciences in Scotland: Academic Industrial Partnerships, Scottish Parliament, Edinburgh Scotland, 26 June 2008
109. Hurko O (2008) Schizophrenia-Related Neuropathology and Behaviour in Transgenic Mice Expressing Truncated DISC1, Wyeth Discovery Day, Stamford, Connecticut
110. Hurko O (2008) Translational Medicine for Multiple Sclerosis, Wyeth Seminars, Collegeville, PA 22 April 2008
111. Hurko, O. (2008) Translational Medicine Research Collaboration, Scottish Labour Party Scientific Forum, Aviemore, Scotland 30 March.2008
112. Sanbing Shen, Bing Lang, Chizu Nakamoto, Feng Zhang, Serena Deiana, Soh-Leh Kuan, Jin Pu, Jacques Micheau, Christina Chatzi, Shui-Sheng He, Iain Mackie, Nicholas J. Brandon, Karen Marquis, Mark Day, Orest Hurko, Colin McCaig, Gernot Riedel and David St Clair (2008) Schizophrenia-related neuropathologies and behaviour in transgenic mice expressing truncated Disc1, 2nd Annual Translational Medicine Investigators Meeting, Glasgow, Scotland
113. Potter D,  Astrid Schloerscheidt, Donna Back, Ludek Nerad, Richard Day, Ben Tatler & Orest Hurko (2008) Translational biomarkers of attention functions, 2nd Annual Translational Medicine Investigators Meeting, Glasgow, Scotland
114. Hurko O (2007) Keynote Address:  The Translational Medicine Research Collaboration (TMRC)  A unique partnership between industry, the National Health Service, & four Scottish Universities. 6th Annual World Drug Discovery & Development Congress, Cologne, Germany 5 December 2007
115. Hurko O (2007) Translational medicine: Universities, the pharmaceutical industry and clinicians meeting the challenge of novel therapeutics, Ninewells Hospital Grand Rounds, Dundee, Scotland 15 November 2007
116. Hurko O (2007) Achieving and enhancing ROI in biomarker research and discovery,  Biomarkers World Asia, Singapore, 19 September 2007
117. Hurko, O (2007) Return on Investment Enquiry on Biomarker Research Oxford International Conference,Manchester, England
118. Hurko, O (2007) The Translational Medicine Research Collaboration  British Heart Foundation, Glasgow, Scotland
119. Hurko, O (2006) Translational Medicine Research Collaboration Scottish Life Sciences Alliance Dundee, Scotland.
120. Hurko, O (2006) Translational Medicine for Neuroscience Clinical Trials in the CNS, London , England.
121. Hurko, O (2006) Strategic Considerations in Biomarker Discovery and Development  Biomarkers Europe. Vienna, Austria
122. Hurko, O (2006) Translational Medicine Research Centre Scottish Enterprise Tayside,Dundee, Scotland.
123. Hurko, O (2006) Strategic Considerations in Biomarker Discovery and Development. European Biomarkers Summit.  Prague, Czech Republic.
124. Hurko O. (2006) Translational Research: from drug targets to personalized medicine.  Society of Chinese Bioscientists in America, San Francisco, California
125. urko, O (2006) Translational Medicine Research Centre: Opportunities for collaboration in Vascular Imaging, Scottish Vascular Imaging Group. Glasgow, Scotland.
126. Hurko O. (2006) Why is drug discovery so hard? What can be learned from failures?  Royal Pharmaceutical Society of Great Britain.  London, England
127. Hurko O (2006) Translational Medicine in Neuroscience.Scottish Neuroscience Group Meeting, Ninewells Hospital, Dundee, Scotland
128. Hurko O (2006) Understanding the Strategic Importance of Biomarkers for the Discovery and Early-Development Phases. Oxford International Biomarker and Discovery Congress, Manchester, England.
129. Hurko O (2006) Drug Development for ALS:  A view from a large Pharmaceutical Company. Robert Packard Center, New York 
130. Hurko O (2005) Drug discovery and development from a corporate prospective.  Amyotrophic Lateral Sclerosis Society, New York
131. Hurko O, Follettie M (2005) Pharmacogenomics and lead selection Cambridge Healthcare Institute: Biomarker Validation and Translational Research. San Francisco, California.
132. Hurko O (2005) Biomarkers: Strategy for translational medicine, International Conference on Drug Development, Barton Creek, Texas.
133. Hurko O (2005) Translational Medicine.  BIO 2005: Thinking ahead in neuroscience, Philadelphia, Pennsylvania
134. Hurko O (2005) Case study: How do you manage the disconnect between what you think you can do in preclinical & what you actually can do in clinical, once regulatory & ethical obstacles have taken their toll.  R&D leaders' Forum, Coral Gables, Florida 
135. Hurko O (2005) Translating concepts into products. CORDIA Biotechnology Conference, London, England.
136. Hurko O (2005) How is the adoption of translational medicine by the pharmaceutical industry improving the efficiency of drug development? Phacilitate Early Development Forum, Berlin, Germany
137. Hurko O (2004) Individualized medicine: science and economics. American Association of Pharmaceutical Sciences, Baltimore, Maryland.
138.  Hurko O (2003) Big Pharma: Re-inventing drug development for the 21st Century. Harvard Biotechnology Club, Cambridge Massachusetts
139. Hurko O. (2003) Industrial-academic interactions in Drug Discovery.  Harvard Business School Summit, Allston, Massachusetts.
140. D.A. Hosford,  A.M. Saunders, N.E. Shepherd, W.A. Strittmatter, R.A. Gibson, O Hurko, L.T. Middleton  A.D. Roses. (2001) Potential use of PET stratification to identify new AD susceptibility genes. First International AD Meeting in the Middle East.
141. Hurko O. (2001)  Drug development for hereditary disorders.  European Biopharma Congress,Munich., Germany
142. Hurko O. (2001) Genomic studies on neuropsychopharmacology: Implications for drug discovery, 2nd ECNP Workshop. Nice, France
143. Hurko O.  Neurogenetics of human disease. (1998)  Genetic Basis of Brain Function: XIth ZMBH Forum, Heidelberg, Germany.
144. Elmaci I, Ain C, Hurko O, Sheppard J, Rigamonti D (1997)  Reoperation in achondroplastic stenosis.  Southern Neurosurgical Society.
145. Hurko O, Felsing N, Kok F, Barr DGD, Rutledge SL, Carson BS, Francomano CA, Krauss G, (1997)  Seizures presenting as apnea in nine infants with achondroplasia (1997)  The 3rd International Skeletal Dysplasia Meeting  Marina del Rey, California.
146. Elmaci I, Ain MC, Hurko O, Sheppard JME, Rigamonti D. (1997)  Comparison of MRI and myelo-CT in the evaluation of spinal stenosis in achondroplasia.  The 3rd International Skeletal Dysplasia Meeting.  Marina del Rey. California.
147. Elmaci I, Ain MC, Hurko O, Lee RR, Shugert E, Rigamomti D, (1997)  Association of syringomyelia and achondroplasia.  The 3rd International Skeletal Dysplasia Meeting.  Marina del Rey, California.
148. Elmaci I, Ain MC, Hurko O, Sheppard JME, Rigamonti D (1997)  Perioperative intracranial hemorrhage in achondroplasia.  The 3rd International Skeletal Dysplasia Meeting.  Marina del Rey, California.
149. Elmaci I, Ain MC, Hurko O, Lee RR, Shugert E, Rigamonti D (1997)  Atlantoaxial dislocation in achondroplasia.  The 3rd International Skeletal Dysplasia Meeting.  Marina del Rey. California.
150. Francomano CA, Bellus, GA, Szabo J, McIntosh I, Dorst J, Lee R, Hurko O, Fraley AE, and Bamshad MJ (1996)  A new skeletal dysplasia with severe tibial bowing, profound developmental delay and acanthosis nigricans is caused by a Lys659Met mutation in fibroblast receptor 3 (FGFR3).  American Journal of Human Genetics  59.
151. Hurko O, Lewanda A, Brusilow SW, (1996)  Cortical blindness following hyperammonemic coma in patients with ornithine trancarbamylase (OTC) deficiency.  The American Journal of Human Genetics 59 (S): A377.
152. Zee DS, Versino M, Hurko O (1996)  Cerebellar patients have ocular misalignment during both fixation and saccades.  XIth International Neuro-ophthalmology Symposium.  Sydney Australia.
153. Hurko O, Polymeropoulos MH, Hsu F, Rubinstein J, Basner S, Lane K,Dietz H, Spetzler RF, Rigamonti D. (1996) :Linkage and haplotype analysis of autosomal dominant cavernous hemangiomas of the brain in four Mexican-American families, Neurology,.
154. Hurko O, Scott A, Amberger J, Bocchini C, Paalman M, Francomano C, Berlowski B, McKusick VA.  Neurogenetics in Online Mendelian Inheritance in Man  Neurology  (1996).
155. Porter NC, Kasper EK, Baughman KL, Hruban R, Hurko O (1996)  Dystrophin analysis in peripartum cardiomyopathy.  American Heart Association.
156. Vandenberg DJ, Persico AM, Gelernter J, Bird GS, Crowe R, Surratt C, Kurlan R, Pauls D, Hurko O, Singer H, Kidd KK, Uhl GR (1993)  Dopamine and vesicular transporter gene markers in neuropsychiatric disorders.  Society for Neuroscience.
157. Walkup JT, MC LaBuda, O Hurko, MA Riddle, HS Singer (1995)  A Family Study and Segregation Analysis of Tourette’s Syndrome: Evidence for a Mixed Model Solution, American Academy of Child and Adolescent Psychiatry.
158. Becher MW, Noll WW, Hurko O, Price DL (1995) Novel 2905-bp mitochondrial DNA deletion in Kearns Sayre syndrome.  J Neuropathology and Experimental Neurology  54: 453.
159. Walkup JT, LaBuda MC, Hurko O., Riddle MA, Singer HS (1995)  Evidence for a mixed model of inheritance in Tourette syndrome.  American Journal of Human Genetics 57(S), October 1995.
160. Crawford TO, Sladky JT, Kelley RI, Hurko O (1995)  Abnormalities in fatty acid metabolism in infants with Type 1 spinal muscular atrophy.  Annals of Neurology 38: 538-539.
161. Persico AM, Vandenbergh DJ, Bird GS, Crowe RR, Surratt CK, Hurko O., Singer HS, Uhl GR (1993)  Dopamine and vesicular transporter gene markers in dopaminergic neuropsychiatric disorders.  World Congress of Psychiatric Genetics.
162. Threlkeld A., Miller NR., Golnick K., Griffin J., Kuncl R., Johns DR., Hurko O (1992) Myo-Neuro-Gastrointestinal Encephalopathy (MNGIE) syndrome: A histopathological characterization and clinical description of a mitochondriopathy associated with ptosis and ophthalmoparesis  ARVO Abstracts.
163. Lebo R., Martelli L., Lynch E. Kong P., Gishkin K., Nicholson G., Golbus M., Hurko O. (1992) Prenatal and presymptomatic diagnosis of Charcot-Marie-Tooth disease Type I..
164. Uematsu S., Hurko O., Kopits S.E., Wang H. (1992)  A total craniospinal decompressive procedure in achondroplastic generalized compression syndrome.  Congress of Neurological Surgeons.
165. Hurko O (1992) Recent advances in neuromuscular genetics.  Child Neurology Society.
166. Uematsu S., Hurko O., Kopits S., Wang H. (1991) A total craniospinal decompressive procedure in achondroplastic compression syndrome.  Congress of Neurological Surgeons,
167. Johns DR., Hurko O., Griffin, JW., Attardi G. (1991)  Molecular basis of a new mitochondrial disease; acute optic neuropathy and myelopathy.  Annals of Neurology.
168. Charnas L., Marini J., Hurko O. (1991) Neurological evaluation of osteogenesis imperfecta Neurology 41: Suppl 1.
169. Nigro, M.A., Lee, C.P., Martens, M., Peterson, P.L., Holmes, R., Change C.H., Chien C., Johns D., Hurko O. (1990)  Mitochondrial cytopathy and cytochrome deficiency: Clinical, ultrastructural, biochemical, and genetic studies.  Neurology40: S295.
170. Johns DR, Brown RH, Rutledge, SL., Hurko O. (1990)  Directly repeated sequences in pathogenetic mitochondrial DNA deletions.  Neurology 40:S.
171. Levin, J.R., Martens M., Lee CP., Nigro MA., Chien C., Ravindranath Y., Johns D., Hurko O. (1990)  Defective complex binding in mitochondrial membrane in a patient with progressive encephalopathy and lactic acidosis Neurology40: S356.
172. Levy L.M., Wang H., Francomano C., Hurko, O., Carson B, Di Chiro G., Bryan R.N. (1990)  The fixed cord in spinal stenosis: MRI of congenital and degenerative diseases.  Radiology.
173. Stine, OC., Smith KD., Hurko O., Johns D.  (1990)  Recombination in animal mitochondrial DNA.  Evolution of genes and genomes Washington DC.
174. Hurko O. (1990)  Recent advances of neuromuscular genetics: an overview.  Journal of Neurological Science 98S: 7.
175. Eleff SM, Barker PB, Chatham SJ, Bryan RN, Hurko O (1990): Phosphorus magnetic resonance spectroscopy of brain in mitochondrial cytopathies.  Annals of Neurology 38: 839.
176. Lee CP., Martens ME., Nigro M., Peterson PL., Holmes R., Chang CH., Chien C., Johns D., Hurko O. (1990)  Deficiency of cytochromes in a patient with mitochondrial encephalomyopathy.  Biophysical Journal 57:  561a.
177. Lebo, R.V., Dyck, P.J., Christian, C.C., Flandermeyer, R.R., Golbus, M.S., Hurko, O., van der Ploeg, M., Anderson, L.A., King, M.C., Chance, P.F., Bird, T.D., Jackson, L.G., Kan, Y.W., Bruce, B.D., Lovelace, R.E., Dickoff, D., Blostein, R., Sadler, J.E., Green, P., Schonberg, S.A., Ionasescu, V., Olney, R.K., Gutman, L., Kadasi, L., Ferak, V., Fowler, W.M., Conneally, P.M. (1989).  The mutilocus Charcot-Marie-Tooth syndrome.  American Journal of Human Genetics, Vol 43, Suppl A149.
178. Eleff, S.M., Barker, P.B., Blackband, S.J., Chatham, J.C., Lutz, N.W., Bryan, R.N., Hurko, O. (1989).  Phosphorus magnetic resonance spectroscopy of patients with mitochondrial encephalomyopathies.  Society of Magnetic Resonance in Medicine, Eighth Annual Meeting, Amsterdam.
179. Johns, D.R., Hurko, O. (1989)  Mitochondrial DNA Analysis in Familial MELAS Syndrome.  Neurology 39: 205.
180. Rosen, S.A., Wang, H., Uematsu, S., Cornblath, D.R.,Hurko O. (1989)  Compression from Hypertrophied Proximal Nerve Roots in Charcot-Marie-Tooth Disease (HMSN 1).  Neurology 39:330.
181. Whitlow, W., Wang, H., Hurko, O., Uematsu, S., Cornblath, D., Balakrishnan, J., Bryan, R.N. (1989) Spinal imaging of Charcot-Marie-Tooth disease.  American Society Neuroradiology, 3D.
182. Lebo, R.V., Dyck, P.J., Chance, P., Bird, T.D., Golbus, M.S., Lynch, E.D., Redila-Flores, M.T., Anderson, L.A., King, M.C., Hall, J.M., Christian, C.C. Flandermeyer, R.R., Hurko, O., Cornblath, D., Johns, D.R., van der Ploeg, M., Weigant, J., Punnett, H.H., Jackson, L.G., Kan, Y.W., Bruce, B.D., Lovelace, R.E., Dickoff, D., Blostein, R., Green, P., Willard, H.F., Schonberg, S.A., Jenkens, L.S., Ionasescu, V., Gutman, L., Kadasi, L., Ferak, V., Fowler, W.M., Conneally, P.M. (1989).  Mapping the Duffy-linked Charcot-Marie-Tooth locus.  Cytogenetics Cell Genetics 51: 1030.
183. Lebo, R.V., Dyck, P.J., Chance, P.F., King, M.C., Lynch, E., Redila-Flores, M. Golbus, M.S., Anderson, L.A., Christian, C.C., Flandermeyer, R.R., van der Ploeg, M., Weigant, J., Hurko, O., Cornblath, D., Johns, D.R., Bird, T.D. Kan, Y.W., Bruce, B.D., Jackson, L.G., Epstein, E., Peltz, G., Moore, K., Shull, M.M., Lingrel, J.B., Green, P., Gendler, S., Latov, N., Lovelace, R.E., Dickoff, D., Blostein, R., Schonberg, S.A., Jenkens, L.S., Ionasescu, V., Gutman, L., Nicholson, G., Kadasi, L,. Ferak, V., Fowler, W.M., Trofatter, J., Conneally, P.M. (1989).  Charcot-Marie-Tooth Locus in Fc>RII Gene Region.  American Journal of Human Genetics 45: A148.
184. Rutledge, S.L., Johns, D.R., Hurko, O. (1989) Mitochondrial DNA analysis in a mitochondrial cytopathy overlap syndrome American Journal of Human Genetics 45: A216.
185. Hurko, O., Johns, D.R., Rutledge, S.L., Stine, O.C. (1989) Directly repeated sequences mediate pathogenic partial deletions of mitochondrial DNA in mitochondrial encephalomyopathies.  EMBO Workshop on Molecular and Cellular Biology of Muscle Development, King’s College Cambridge.
186. Hurko, O. (1988)  Mitochondrial cytopathies: Ophthalmoplegia plus and Lebers.  In, Zee D, Course Director, Neuroopthalmology course at the American Academy of Neurology, Cincinnati.
187. Hurko, O., Hoffman, E., McKee, L., Johns, D.R., Kunkel, L. (1988).  Dystrophin expression in muscle cells cloned from a Duchenne carrier heterozygous for G6PD.  American Journal of Human Genetics. Vol 43, Suppl.: A8.
188. Hurko, O., Reynafarje, B., Kunel, R., McKee, L., Feldman, E. (1987).  Defective cytochrome oxidase activity in siblings from a pedigree suggestive of matroclinal inheritance and heteroplasmy, in Molecular Biology of Mitochondria and Chloroplasts.  Cold Spring Harbor Laboratory, New York.
189. Hurko, O., Cox, R., Wong, H., Walsh, F., Quinn, C.  (1986).  Somatic cell genetic analysis of human muscle membranes.  Muscle and Nerve  9: 159.
190. Hurko, O., Feldman, E., Kunel, R., Caplan, S., Stern, B., Krumholz, A. (1986).  Mitochondrial encephalomyopathy, lactic acidosis and stroke: multiple instances within a kindred.  Muscle and Nerve 9: 179.
191. Zuurveld, J., McKee, L., Walsh F., Hurko, O. (1986).  Fluorescence-activated cell sorting of human skeletal muscle.  Muscle and Nerve 9: 163.
192. Hurko, O., McKee, L., Zuurveld, J.  (1986). Comparison of Duchenne and normal myoblasts from a single heterozygote.  Neurology 36: S300.
193. Tennekoon, G., Hurko, O., Barbosa, E., Peden, K. (1986).  Use of SV40 large T antigen gene under the control of the metallothionein promoter to produce cell lines.  Sixth Oholo Conference, Israel.
194. Reid, CS., Marie BL., McPherson, RW., Winfield, J., Wang, H., Pyeritz, RE., Hurko, O.  (1985). Pediatric patients with achondroplasia at risk for cervicomedullary cord compression.  Canadian Neurological Congress. Montreal.
195. Hurko, O., McKee, L (1985).  Simultaneous expression of T antigen and muscle-specific proteins in transfected human cells.  Neurology 35: (Suppl 1): 166.
196. Hurko, O., McKee, L., Zuurveld, J., Peden, K. (1985).  Oncogene transfection of human skeletal muscle.  Journal of Neurology  232 (suppl.): 172.
197. Hurko O, Walsh FS (1984)  Diseases of Muscle. In: Molecular Biology and Human Disease (Editors: MacLeod, A.K. and Sihora, K.) Blackwell Scientific Publications Ltd., Oxford, pp. 211-239.
198. Walsh FS., Moore SE, Woodroofe, MN, Hurko O, Nayak R (1983).  Developmentally regulated antigens of human muscle.  EMBO meeting on Muscle Development.
199. Walsh, FS, Moore SF, Woodroofe, MN, Hurko, O., Nayak R., Brown SM (1983)  Developmentally regulated antigens of human muscle  Second Annual Congress for Hybridoma Research.
200. Walsh, FS, Hurko O (1983)  Searching for the Cause of Duchenne Dystrophy.  In: Research at the National Hospitals for Nervous Diseases and the Institute of Neurology, National Hospitals for Nervous Diseases (Queen Square), London, pp 73-78.
201. Hurko, O., Walsh FS (1982) Immunologic analysis of developing and regenerating human muscle fibers.  In Proceedings of the Fifth International Symposium on Neuromuscular Diseases.
202. Woodroofe, MN, Dhut, S., Hurko, O., Modi, G, Walsh FS (1982)  A monoclonal antibody to type II muscle fibers.  In: Proceedings of the Fifth International Symposium on Neuromuscular Diseases.

Book Chapters

203. Wan, HI  Kling MA, Day M, Chavez J, Feuerstein G, , Hurko O, Pangalos M  (2011) In, Imaging in CNS Drug Discovery and Development: Implications for Disease and Therapy, Eds:David Borsook, Lino Becerra, Edward Bullmore , Richard Hargreaves, Springer Science, in the press
204. Hurko O (2006)  Genetic neurologic disorders in females.  In, Neurologic Disease in Women,  2nd edition (PW Kaplan, ed.), New York: Demos,  pp.91-114.
205. Hurko O (2002) Genetics of common neurological disorders, in Diseases of the Nervous system: Clinical Neurobiology, 3rd Edition(Editors: Asbury, AK., McKhann, GM, MacDonald, WI,  Goadsby, PJ, McArthur, JM, , Cambridge: Cambridge University Press), pp 14-31.
206. Hurko O (1999) Genetic disorders, In, Neurological Disease in Women; a Comprehensive Textbook (PW Kaplan, ed.)
207. Hurko O, Provost   TT (1999) Neurology and the skin In Neurology & Medicine, (Editors Richard A.C. Hughes and David Perkin) Blackwell
208. Hurko O (1996) Syringomyelia.  In Current Therapy in Neurologic Disease – 7 (Editor RT Johnson & Griffin J) BC Decker, Philadelphia pp 110-114.
209. Carson BS, Francomano C, Lauer JA, Hurko O (1995)  Management of achondroplasia and its neurosurgical complications.  In Operative Neurosurgical Techniques, 3rd Edition.  (Eds. Schmidek HH and Sweet WH) WB Saunders, Philadelphia, pp. 2107-2118.
210. Hurko O (1995) Dwarfism.  In, Academic American Encyclopedia; Ed. S. Randel, Grolier Inc, Danbury.
211. Hurko O. (1992) Heritable disorders of the nervous system.  In: Diseases of the Nervous System: Clinical Neurobiology, 2nd Ed (Editors; A Asbury, WI MacDonald, GM McKhann) Saunders, Philadelphia.pp 656-669.
212. Peterson PL, Lee CP, Hurko O (1992) Mitochondrial encephalmyopathies.  In: The Handbook of Cerebellar Diseases(Editor: R. Lechtenberg) Marcel Decker: New York.
213. Hurko O (1992) Brain and nervous system: Cerebrovascular disease; Alzheimer’s disease. In: Health and Medicine Annual, (Ed. K. Fairchild) Grolier Press: Danbury.
214. Hurko, O (1992) Heritable ataxias.  In, Current Therapy in Neurologic Disease – 5 (Editor: R.T. Johnson) B.C. Decker, Philadelphia.
215. Hurko O (1991) Brain and nervous system: genetic diseases of the nervous system: AIDS and the brain in: Health and Medical Horizons  1991 (Ed. CM Grove) MacMillan, New York.
217. Hurko, O. and Peterson, P.L. (1990) Mitochondrial Encephalomyopathies.  In: Current Therapy in Neurologic Disease –3 (Editor R.T. Johnson) B.C. Decker, Philadelphia, pp 357-360.
218. Hurko, O. (1989). Permanent differentiated cell lines from human biopsy material.  In Vitro Toxicology: New Directions (A.Goldberg, Ed.) Mary Ann Liebert, New York, pp 83-96.
219. Uematsu, S and Hurko, O. (1989).  Neurological complications of Achondroplasia; neurosurgical aspects.  In:  Current Therapy in Neurological Surgery(Editor: Long, DM) BC Decker, Toronto, pp 226-228.
220. Hurko O (1989) Neurological Diseases, in Johns Hopkins Family Health Book, (Michael J Klag, Ed) Harper Collins, New York.
221. Peden, K., Hurko, O., and Tennekoon, G. (1987).  Establishment of cell lines from primary cultures by transfection with SV40 large T antigen gene, in Model Systems in Neurotoxicology: Alternative Approaches to Animal Testing. (Editors: Shahar A. and Goldberg A.M) Alan R. Liss, Inc, New York, pp 101-109.
222. Hurko, O. and McKhann, G.M. (1986). Presentation of inherited metabolic diseases.  In: Clinical Neurobiology (Editors: Asbury, AK, MacDonald, WI, McKhann, GM) Philadelphia: Saunders) pp. 780-794.
223. Hurko, O., McKee, L., Zuurveld, J.G.E.M., Walsh, F.S., and Swick, H.M (1986).  Proliferative capacity of Duchenne and wild-type myoblasts derived from a DMD-G6PD double heterozygote, in Molecular Biology of Muscle Development (Editors: Emerson, C., Fischman, D.A., Nadal-Ginard, B., Siddiqui, and M.A.Q.) Alan Liss, Inc., New York, pp. 921-928.
224. Hurko, O. (1985) Management of metabolic myopathies.  In Current Therapy in Neurologic Disease (Editor Johnson, RT) BC Decker, Toronto, pp. 383-387.
225. Walsh, F.S., Hurko, O., Quinn, C.A., and Brown, S.M. (1984). X-chromosome coded antigens in Duchenne muscular dystrophy.  In: Neuromuscular Diseases (Editor: Serratrice, G.) Raven Press, New York, pp. 119-122.
226. Walsh, F.S., Quinn, C.A., Yasin R., Thompson, E.J., and Hurko, O. (1982). Human muscle antigens during development.  In: Muscle Differentiation (Editor: M.Pearson) Cold Spring Harbor Laboratory, New York, pp. 535-542.

Books

227. McKusick VA, Antonarakis SE, Francomano CA, Hurko O, Scott AF, Smith M, Valle D. (1998)  Mendelian Inheritance in Man: A catalog of human genes and genetic disorders, Twelfth Edition.  Baltimore: The Johns Hopkins University Press.
228. Slavney PR, Hurko O (2001) The Primary Care Physician's Guide to Common Psychiatric and Neurologic Problems.  Baltimore: The Johns Hopkins University Press.

Patents

229. Rutkowski, JL, Jacobsen S. Hurko (2006) PET and magnetic resonance for screening Alzheimer’s disease therapeutics. WO/2006/052691. International Application No.: PCT/US2005/039865

Electronic

230. Hurko O (2010) Phase I Clinical Trials, Thomson Reuters.
231. Hurko O (2009) Biomarkers in Brain Disease, Thomson Reuters.
232. Snyder PJ, Thal L,  Albert  M, Hurko O, Schmidt M, Peterson R, Morris J, Hargreaves R, Grundman M (2002) Working Group on Study Design - Summary of Findings. Study Design, Subject Characterization, Neuropsychological Measures & Statistical Issues Working Group NIA AD Neuroimaging Initiative , http://www.nia.nih.gov/ResearchInformation/ExtramuralPrograms/ NeuroscienceOfAging/Working+Group+on+Study+Design+-+Summary+of+Findings.htm
233. Contributions to over 250 entries in Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim/.
234. “The New Word on Concussions in Sports”, Johns Hopkins/ IntelliHealth News Commentary, http:..www.pointcast.com.
235. Itzhaki R, Sigurdsson E, Morgan D, Ugen K, Atwood C, Flavio Kamenetz F, Jon Oscherwitz J, Crutcher K,  Bowen R, Strobel G, Troncoso J, Koudinov A, Sugaya K, Matsuoka Y, Travis J, Bishop G, Steve Snyder S,, Hurko O, Hejna M, Pasinetti G, Spooner E, Leverone J, Zhang J, Klee MA.(2002) Alzheimer Immunotherapy Trial Grounded: Time to Reassess Safety and Vaccine Design.  Alzheimer Research Forum.http://www.alzforum.org/res/for/ journal/transcript.asp?LiveID=98
236. Hurko O. (2001) Stem Cell Transplantation for Spinal Muscular Atrophy. The Jennifer Trust for Spinal Muscular Atrophy